LongeVC, an international investor based in Latvia, has injected an unspecified sum into Cambridge company Constructive Bio ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative therapeutic approaches capable of addressing multiple metabolic pathways ...

Nurx, a leading telehealth platform specializing in women's health, is excited to announce an integration agreement with ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

For patients with inadequately controlled T2D receiving dulaglutide, switching to tirzepatide is associated with additional HbA1c reduction and weight loss.

"I've said this before, but as more data comes in I become more convinced that we may look back on these drugs as the ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

Switching to tirzepatide associated with hemoglobin A1c reduction and weight loss compared with escalating treatment with dulaglutide.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.